Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05071313 · ClinicalTrials.gov registry record · Phase 3
A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older
A Phase 3 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 777
- Enrollment target
NCT05071313 is a Phase 3 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 777 participants.
The verdict
NCT05071313, a Phase 3 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 777 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the immunogenicity and safety of Ad26.RSV.preF-based vaccine and quadrivalent high-dose seasonal influenza vaccine when administered either concomitantly or separately.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Ad26.RSV.preF-based vaccine
- BIOLOGICAL Quadrivalent High-dose Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 777 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2022-10-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05071313
The ClinicalTrials.gov registry entry for NCT05071313 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 777 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05071313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05071313 about?
NCT05071313 is a clinical study titled "A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older". The purpose of this study is to evaluate the immunogenicity and safety of Ad26.RSV.preF-based vaccine and quadrivalent high-dose seasonal influenza vaccine when administered either concomitantly or separately.
What is the current status of trial NCT05071313?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 777 participants. The study started on 2021-10-04. Estimated completion is 2022-10-11.
What interventions are being tested in trial NCT05071313?
The interventions under investigation include: Placebo (BIOLOGICAL), Ad26.RSV.preF-based vaccine (BIOLOGICAL), Quadrivalent High-dose Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05071313?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.